Streetbeat News

Analyst Ratings

DOCU

DocuSign shares are trading lower after UBS maintained a Sell rating on the stock and lowered its price target from $52 to $45.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 1:05 pm

BLUE

Grizzly Research published a report on bluebird bio, criticizing the company's management and raising concerns about its gene therapy products. The report caused bluebird bio's shares to fall.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 1:04 pm

GMED

Analysts have provided ratings for Globus Medical (NYSE:GMED) within the last quarter, with an average price target of $64.5, implying upside from the current price of $52.61. The current average has decreased by 0.77% from the previous average price target of $65.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:03 pm

NVRO

In the last quarter, Nevro (NYSE:NVRO) received 3 somewhat bullish, 7 indifferent, and 1 somewhat bearish analyst ratings. The company has an average 12-month price target of $40.64, a 0.47% decrease from the previous average of $40.83.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:03 pm

AMLX

Amylyx Pharma (NASDAQ:AMLX) has received 6 bullish and 1 indifferent analyst ratings in the last quarter, with an average 12-month price target of $50.43, up 5.06% from the previous average of $48.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:02 pm

ALNY

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, with an average price target of $270.4, implying an upside from the current price of $186.46. The current average has increased by 34.08% from the previous average price target of $201.67.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:01 pm

BOX

In the last quarter, Box (NYSE:BOX) received 3 somewhat bullish and 2 somewhat bearish ratings from analysts. The average 12-month price target for Box is $28.2, a 17.5% increase from the previous average of $24.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:01 pm

CVNA

Carvana (NYSE:CVNA) has received 4 somewhat bullish and 2 indifferent analyst ratings in the last quarter, with an average price target of $14.33, implying an upside from the current price of $13.72. The average price target has increased by 6.15% from the previous average of $13.50.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:00 pm

HPP

SBRA

SLG

Wall Street's most accurate analysts recommend holding three high-dividend-yielding real estate stocks: Hudson Pacific Properties (HPP), SL Green Realty (SLG), and Sabra Health Care REIT (SBRA). All three companies reported better-than-expected sales results for their first quarters.

Portfolio Pulse from Lisa Levin

May 31, 2023 | 1:00 pm

CPRI

Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on Capri Holdings (NYSE:CPRI) and maintained a $55 price target.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:54 pm